NCT05016778 - A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2025

Conditions

Multiple Myeloma

Interventions

DRUG

GPRC5D-CAR-T

After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.

Trial Locations (1)

310003

The first affiliated hospital of medical college of zhejiang university, Hangzhou